Regentis Biomaterials RGNT
NYSE RGNT
$2.00 +0.00 (+0.01%)
As of: Sep 9, 2026 · 3:58 PM EDT

Regentis Biomaterials (RGNT) Enterprise Value (2025)

Regentis Biomaterials' (RGNT) quarterly Enterprise Value came in at -$3.6 million in Q4 2025.

Analysis

Regentis Biomaterials (RGNT) Enterprise Value (2025) Analysis & Trends

Regentis Biomaterials (RGNT) has reported Enterprise Value for 1 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Enterprise Value changed N/A year-over-year to -$3.6 million in Q4 2025; TTM through Dec 2025 was -$3.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$3.6 million, changed N/A from the prior year.
  • Enterprise Value was -$3.6 million for Q4 2025 at Regentis Biomaterials.
  • Over five years, Enterprise Value peaked at -$3.6 million in Q4 2025 and troughed at -$3.6 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn
10 Regentis Biomaterials 1.12 Mn -6.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.56 Mn